In this episode of Breaking Protocol, Ram Yalamanchili sits down with Paula Brown-Stafford, CEO of Allucent and one of the early architects of the CRO industry.

From joining Quintiles as its 23rd employee to leading a purpose-built CRO focused on biotech innovation, Paula shares how the industry evolved from pure operational execution to intelligence-driven partnership. She explains why the real differentiator today is not scale, but regulatory intelligence, therapeutic depth, and the ability to navigate complex rare disease and cell and gene therapy trials.

The conversation also examines the economics of drug development, shifting regulatory pathways, and how AI teammates can reduce time and cost without compromising quality. For sponsors facing capital constraints and increasing pressure to deliver results, this episode offers a grounded perspective on how the CRO model must evolve to create measurable strategic advantage.

If you are leading clinical development, R&D, or portfolio strategy, this discussion will challenge how you think about partnership, value, and execution.